Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.

@article{Reilly2012PharmacologyOM,
  title={Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.},
  author={Regina M. Reilly and Heath A. McDonald and Pamela S. Puttfarcken and Shailen K. Joshi and LaGeisha R Lewis and Madhavi Pai and Pamela H Franklin and Jason A. Segreti and Torben R. Neelands and Ping Han and Jun Chen and Patrick W Mantyh and Joseph R. Ghilardi and Teresa M Turner and Eric A Voight and Jerome F Daanen and Robert G Schmidt and Arthur R Gomtsyan and Michael Kort and Connie R. Faltynek and Philip R. Kym},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2012},
  volume={342 2},
  pages={416-28}
}
The transient receptor potential vanilloid-1 (TRPV1) channel is involved in the development and maintenance of pain and participates in the regulation of temperature. The channel is activated by diverse agents, including capsaicin, noxious heat (≥ 43°C), acidic pH (< 6), and endogenous lipids including N-arachidonoyl dopamine (NADA). Antagonists that block all modes of TRPV1 activation elicit hyperthermia. To identify efficacious TRPV1 antagonists that do not affect temperature antagonists… CONTINUE READING